Lonza wins exclusive 5-year manufacturing contract from Index ventures

- Last updated on GMT

Lonza wins exclusive 5-year manufacturing contract from Index ventures
Lonza has been selected to develop and manufacture all biologics for the biotech companies in capital investment firm Index Ventures' portfolio.

The venture firm announced it had entered into an exclusive agreement with the Switzerland-headquartered contract manufacturing organization (CMO) Lonza this morning. The five-year deal will see Lonza fulfill all process development and GMP production of biological products in the portfolio of companies where Index is the major investor.

According to Dr. Stephan Kutzer, COO Lonza Pharma & Biotech, “this multi-product agreement demonstrates Lonza's ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product lifecycle.”

Kevin Johnson, Partner at Index Ventures said Lonza had been selected in part due to previous antibody products he had worked on in the last 20 years and this deal will enable Index’ asset-centric portfolio companies “to benefit as though they were much larger organisations.”

According to its website​, Index has 31 mostly start-up and small biotech Life Science companies in its portfolio. 

Related news

Show more

Related products

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...